Floatz logo

Busulphan

Congenital Amegakaryocytic Thrombocytopenia

University of California, San FranciscoPhase 2Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Congenital Amegakaryocytic Thrombocytopenia cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
METHOTREXATE
Fred Hutchinson Cancer Center
Phase 2BB
Thiotepa
Fred Hutchinson Cancer Center
Phase 2BB
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2B
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2B

View all 13 →

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →